[Federal Register Volume 69, Number 76 (Tuesday, April 20, 2004)]
[Notices]
[Pages 21117-21121]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-8875]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Monitoring Atypical HIV Strains Among Persons Newly Diagnosed
With HIV Using Dried Blood Spots vs. Diagnostic Sera
Announcement Type: New.
Funding Opportunity Number: 04118.
Catalog of Federal Domestic Assistance Number: 93.944.
Key Dates: Letter of Intent Deadline: May 20, 2004. Application
Deadline: June 21, 2004.
I. Funding Opportunity Description
Authority: This program is authorized under the Public Health
Service Act sections 301 and 318(b) (42 U.S.C. 241 and 247c), as
amended.
Purpose: The purpose of the program is to expand the ability of
health departments to perform surveillance of the prevalence of
atypical strains of HIV, including drug resistant strains and non-B
subtypes, by piloting the use of dried blood spots as an additional
specimen type for this purpose. The use of serum from an HIV diagnostic
blood draw for surveillance of atypical strains is the methodology used
in several HIV resistance surveillance projects in various stages of
implementation with different health departments. Some diagnostic sites
and clinical centers cannot currently be included in these projects,
due to logistical problems with specimen availability, processing or
volume. The purpose of CDC funding for this activity is to allow state
and local health departments, including both those already
participating in atypical HIV strain surveillance and those not yet
participating, to:
(1) Evaluate the feasibility and efficiency of routine use of dried
blood spots (DBS) for surveillance of atypical strains of HIV,
including drug resistant strains and non-B subtypes, in persons newly
diagnosed with HIV.
(2) Monitor the prevalence of atypical HIV strains, including
antiretroviral drug resistant strains and non-B subtypes, among persons
newly diagnosed with HIV, including those for whom sera from a
diagnostic blood draw are not available for surveillance purposes, and
those for whom diagnostic sera are used for surveillance of atypical
strains.
Compare the prevalence among the two groups.
This project will fulfill the purpose of monitoring prevalence of
atypical strains by extending surveillance to sites that would
currently be unable to provide sera for genotyping. DBS may also be
collected for atypical strain surveillance in other sites where the
collection of DBS may be more acceptable or require fewer resources
than the collection of diagnostic sera. A comparison of resource
requirements for the two methods in a variety of site types will be an
important part of the evaluation. This program addresses the ``Healthy
People 2010'' focus area(s) of HIV.
Measurable outcomes of the program will be in alignment with one
(or more) of the following performance goal(s) for the National Center
for HIV, STD, and TB Prevention (NCHSTP): Strengthen the capacity
nationwide to monitor the epidemic, develop and implement effective HIV
prevention interventions and evaluate prevention programs.
The expected outcome is an enhanced ability to collect data on
atypical HIV strains in persons newly diagnosed with HIV. Data from
surveillance of atypical strains of HIV are used to identify emerging
epidemics, monitor trends in transmission, target prevention resources
and interventions to areas and populations most heavily affected, and
evaluate programs designed to prevent the transmission of HIV.
Research Objectives: (1) To monitor the prevalence of HIV drug
resistant strains and non-B HIV-1 subtypes in persons newly diagnosed
with HIV in public or private settings, including those in which sera
are not available for HIV genotyping and those in which sera are used.
(2) To compare the results of HIV genotyping for atypical strain
surveillance purposes from both a serum or plasma specimen and a dried
blood spot collected not more than three months after diagnosis for at
least 20 newly diagnosed persons per area.
(3) To compare the prevalence of atypical strains of HIV among
persons diagnosed at sites where HIV diagnostic specimens are used for
HIV drug resistance and subtype surveillance, and sites where HIV
diagnostic specimens cannot be used, such as:
a. Sites where blood draws are not used for HIV diagnosis.
b. Sites where blood draw volumes are consistently too low for 1 ml
of serum to be set aside for HIV genotyping for the purpose of atypical
strain surveillance.
c. Sites where the use of sera from the diagnostic blood draw for
HIV genotyping is not practical because the time between blood draw and
processing is consistently greater than 96 hours, rendering the
amplification of virus for HIV drug resistance genotyping problematic.
d. Sites where the use of DBS for atypical HIV strain surveillance
is more acceptable than the use of sera to staff or participants, or
where fewer resources may be required to collect DBS than sera.
(4) To evaluate the resources needed and the logistics involved in
collecting and transporting specimens and amplifying HIV for genotyping
from DBS, compared with using HIV diagnostic sera, for routine atypical
HIV strain surveillance.
Activities: Awardee activities for this program are as follows:
1. Identify HIV diagnostic sites, Counseling, Testing and Referral
Centers, and/or clinical sites where HIV drug resistance surveillance
in newly diagnosed persons cannot take place using the serum/plasma
based methodology funded under PA 01194, PA 04017, and PA 00005 because
of one of the following conditions:
a. Blood draws are not used for HIV diagnosis.
b. Blood draw volumes are consistently too low for 1 ml of serum to
be set aside for HIV drug resistance genotyping.
c. The use of sera from the diagnostic blood draw for HIV
genotyping is not practical because the time between blood draw and
processing is consistently greater than 96 hours, rendering the
amplification of virus for HIV drug resistance genotyping problematic.
d. DBS are more acceptable to staff or participants, or their
collection, processing, and transport may require fewer resources than
sera.
2. Identify the subset of those sites from which DBS could be
obtained for equal to or greater than 90 percent of persons newly
diagnosed with HIV in each site, either at the time of HIV diagnosis or
no more than three months after diagnosis.
3. Identify comparison sites from which HIV diagnostic sera are
being used, or can be used, for routine surveillance of atypical
strains of HIV, in which logistics, resources, and staff time needed to
collect and process specimens can be compared to those in sites where
DBS will be collected. These sites may include, but are not limited to,
sites already participating in atypical
[[Page 21118]]
HIV strain surveillance under PA 00005, PA 01194, or PA 04017.
4. Identify one or more sites in which paired specimens (sera or
plasma + DBS) can be collected no more than three months after
diagnosis from at least 20 persons newly diagnosed with HIV annually.
(Note that the paired specimens may be collected from a blood draw
required for routine surveillance or clinical purposes no more than
three months following diagnosis, but need not necessarily be collected
as part of a diagnostic blood draw.)
5. Develop and implement (after appropriate ethics review) a
protocol to obtain and transfer DBS from selected sites identified in
(2), sera from sites identified in (3), and at least 20 paired
specimens consisting of sera or plasma + DBS from any atypical strain
surveillance site, to a laboratory collaborating with CDC and local
health department staff on surveillance of HIV drug resistance in newly
diagnosed persons through HIV drug resistance genotyping under PA
00005, PA 01194, or PA 04017.
6. Record or download minimum specimen tracking and non-identifying
demographic and clinical information, in formats currently used in HIV
drug resistance surveillance funded under 00005, 01194, and 04017, to
be transferred to CDC.
7. Make available the option for each participant to designate a
provider to receive a clinician-friendly hard copy report of HIV drug
resistance and subtype results from the genotyping laboratory, similar
to that currently produced in current HIV drug resistance surveillance
protocols.
8. Store HIV drug resistance genotyping data electronically and
analyze them along with risk factor information for use in HIV
prevention and public health programs.
9. Record minimum data to evaluate labor and resources used to
collect and process DBS, and to collect and process diagnostic sera,
for surveillance of atypical strains of HIV.
10. Collaborate with CDC in analyzing the data.
11. Provide results and share data with network participants, other
collaborators in the field, and with CDC.
12. Attend an annual meeting to discuss project activities and
methods for data and specimen collection to facilitate representative
surveillance.
13. Collaborate with CDC in evaluating the feasibility and
efficiency of using DBS to supplement or replace serum-based
surveillance to monitor prevalence of HIV drug resistance and non-B HIV
subtypes in persons newly infected or newly diagnosed with HIV. Further
collaborate with CDC in planning the extension of the method as part of
routine surveillance of atypical HIV strains, if the method proves
successful and if funds are available.
In a cooperative agreement, CDC staff is substantially involved in
the program activities, above and beyond routine grant monitoring.
CDC Activities for this program are as follows:
1. Assist in the development of a protocol or project description
for Institutional Review Board (IRB) review at all cooperating
institutions participating in the project to request a non-research
determination. The IRB review at each cooperating institution will be
done by an Office of Human Research Protection (OHRP)-approved IRB with
either a single, multiple, or Federal-wide project assurance. The CDC
IRB will review and approve the protocol initially and on at least an
annual basis until the project is completed, or until a non-research
determination is received.
2. Provide assistance in the design and conduct of the project and
statistical analysis.
3. Provide assistance in training, if requested.
4. Provide assistance in locating or contracting with a laboratory
participating in CDC-funded HIV drug resistance surveillance genotyping
to provide HIV genotypic testing of the DBS and sera (or plasma). Work
with participating laboratories to develop laboratory procedures to
extend and validate current HIV genotyping methods for use with DBS.
5. Assist in the analysis of the data and the presentation and
publication of results.
6. Collaborate with participants in evaluating the feasibility and
cost effectiveness of using DBS to supplement or replace collection of
diagnostic sera to monitor prevalence of atypical strains in persons
newly infected or newly diagnosed with HIV. Further collaborate in
planning the extension of the project as a long-term network, if the
pilot is successful and if funds are available.
II. Award Information
Type of Award: Cooperative agreement.
CDC involvement in this program is listed in the Activities Section
above.
Fiscal Year Funds: 2004.
Approximate Total Funding: $500,000.
Approximate Number of Awards: Six.
Approximate Average Award: $83,000 (This amount is for the first
12-month budget period, and includes both direct and indirect costs).
Floor of Award Range: None.
Ceiling of Award Range: $200,000 (This ceiling is for the first 12-
month budget period.)
Anticipated Award Date: September 1, 2004.
Budget Period Length: 12 months.
Project Period Length: Five years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal government.
III. Eligibility Information
III.1. Eligible Applicants
Applications may be submitted by health departments of States, U.S.
territories or their bona fide agents, including the District of
Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, and the
six independently-funded city health departments of Chicago, Houston,
Los Angeles, New York City, Philadelphia, and San Francisco.
A Bona fide agent is an agency/organization identified by the State
as eligible to submit an application under the State eligibility in
lieu of a State application. If you are applying as a bona fide agent
of a State or local government, you must provide a letter from the
State or local government as documentation of your status. Place this
documentation behind the first page of your application form.
Areas conducting these activities must have a sufficient volume of
newly diagnosed HIV cases in order to assess the correlation in results
between DBS and sera or plasma with adequate statistical precision.
Eligible applicants are limited to areas that have a HIV case
reporting system in place as of April 1, 2004.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
CDC will accept and review applications with budgets greater than
the ceiling of the award range.
If your application is incomplete or non-responsive to the
requirements listed in this section, it will not be entered into the
review process. You will be notified that your application did not meet
submission requirements.
Individuals Eligible to Become Principal Investigators: Any
individual
[[Page 21119]]
with the skills, knowledge, and resources necessary to carry out the
proposed research is invited to work with their institution to develop
an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for CDC programs.
Note: Title 2 of the United States Code section 1611 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 5/2001). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) Web site at the following
Internet address: http://grants.nih.gov/grants/funding/phs398/
phs398.html.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: (770) 488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Application Submission
Letter of Intent (LOI): Your LOI must be written in the following
format:
Maximum number of pages: three.
Font size: 12-point unreduced.
Single spaced.
Paper size: 8.5 by 11 inches.
Page margin size: One inch.
Printed only on one side of page.
Written in plain language, avoid jargon.
Your LOI must contain the following information:
Descriptive title of the proposed research.
Evidence that at least 40 cases of HIV were
diagnosed in the area in the latest 12 months for which data are
available, accompanied by a brief description of the method by which
the figures were obtained (including the elimination of duplicates).
Name, address, e-mail address, and telephone
number of the Principal Investigator.
Names of other key personnel.
Participating institutions.
Number and title of this Program Announcement
(PA).
Application: Follow the PHS 398 application instructions for
content and formatting of your application. For further assistance with
the PHS 398 application form, contact PGO-TIM staff at (770) 488-2700,
or contact GrantsInfo, telephone (301) 435-0714, e-mail:
[email protected].
Your research plan should address activities to be conducted over
the entire five-year project period. Your detailed line-item budget
narrative should cover the costs of activities for first one-year
budget period.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal Government. Your DUNS number must be entered
on line 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely identifies
business entities. Obtaining a DUNS number is easy and there is no
charge. To obtain a DUNS number, access www.dunandbradstreet.com or
call 1-866-705-5711.
For more information, see the CDC Web site at: http://www.cdc.gov/
od/pgo/funding/pubcommt.htm.
This PA uses just-in-time concepts.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
LOI Deadline Date: May 20, 2004.
CDC requests that you send a LOI if you intend to apply for this
program. Although the LOI is not required, not binding, and does not
enter into the review of your subsequent application, the LOI will be
used to gauge the level of interest in this program, and to allow CDC
to plan the application review.
Application Deadline Date: June 21, 2004.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. eastern time on the deadline
date. If you send your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery of the application by the closing date
and time. If CDC receives your application after closing due to: (1)
Carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the application as having
been received by the deadline.
This announcement is the definitive guide on application submission
address and deadline. It supersedes information provided in the
application instructions. If your application does not meet the
deadline above, it will not be eligible for review, and will be
discarded. You will be notified that your application did not meet the
submission requirements.
CDC will not notify you upon receipt of your application. If you
have a question about the receipt of your application, first contact
your courier. If you still have a question, contact the PGO-TIM staff
at: 770-488-2700. Before calling, please wait two to three days after
the application deadline. This will allow time for applications to be
processed and logged.
IV.4. Intergovernmental Review of Applications
Your application is subject to Intergovernmental Review of Federal
Programs, as governed by Executive Order (EO) 12372. This order sets up
a system for State and local governmental review of proposed Federal
assistance applications. You should contact your State single point of
contact (SPOC) as early as possible to alert the SPOC to prospective
applications, and to receive instructions on your State's process.
Click on the following link to get the current SPOC list: http://
www.whitehouse.gov/omb/grants/spoc.html.
IV.5. Funding Restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows:
Funding cannot be used for purchase of major laboratory equipment
for the performance of HIV genotyping. (Laboratory supplies and labor
for specimen processing may be included.)
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement should be less than 12
months of age.
Awards will not allow reimbursement of pre-award costs.
IV.6. Other Submission Requirements
LOI Submission Address: Submit your LOI by express mail, delivery
service, fax, or e-mail to: Andrew Vernon,
[[Page 21120]]
Scientific Review Administrator, CDC, National Center for HIV, STD and
TB Prevention, Office of the Associate Director for Science, 1600
Clifton Road, Mail-Stop E-07, Atlanta, Georgia, 30333; telephone
number: 404-639-8000, fax: 404-639-8600, e-mail address:
[email protected].
Application Submission Address: Submit the original and five hard
copies of your application by mail or express delivery service to:
Technical Information Management-PA 04118, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria
You are required to provide measures of effectiveness that will
demonstrate the accomplishment of the various identified objectives of
the cooperative agreement. Measures of effectiveness must relate to the
performance goals stated in the ``Purpose'' section of this
announcement. Measures must be objective and quantitative, and must
measure the intended outcome. These measures of effectiveness must be
submitted with the application and will be an element of evaluation.
The goals of CDC-supported research are to advance the
understanding of biological systems, improve the control and prevention
of disease and injury, and enhance health. In the written comments,
reviewers will be asked to evaluate the application in order to judge
the likelihood that the proposed research will have a substantial
impact on the pursuit of these goals.
The scientific review group will address and consider each of the
following criteria in assigning the application's overall score,
weighting them as appropriate for each application. The application
does not need to be strong in all categories to be judged likely to
have major scientific impact and thus deserve a high priority score.
For example, an investigator may propose to carry out important work
that by its nature is not innovative, but is essential to move a field
forward.
The criteria are as follows:
Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
Approach: Applicants should demonstrate the ability to collect
adequate numbers of DBS and sera specimens.
1. Areas having at least 100 newly diagnosed cases of HIV annually
should demonstrate that they are able to provide all of the following:
a. At least 80 specimens (sera, plasma, or DBS) annually for
atypical strain surveillance.
b. At least 30 dried blood spot specimens annually.
c. At least 20 paired sera or plasma + DBS annually.
2. Areas having 40-99 cases of HIV diagnosed annually should
demonstrate that they are able to provide ALL of the following:
a. Specimens (sera, plasma, or DBS) from at least 80 percent of
newly diagnosed cases annually for atypical strain surveillance.
b. DBS specimens from at least 20 HIV cases reported in the state
or local area annually.
c. At least 20 paired sera or plasma /DBS specimens (these may
include specimens in categories 2b and 2c).
Other issues to be examined in applicant's approach include:
Are the conceptual framework, design, methods,
and analyses adequately developed, well-integrated, and appropriate to
the aims of the project?
Does the applicant acknowledge potential problem
areas and consider alternative tactics?
Is there evidence that the health department has
an agreement to collaborate with one or more sites in the area to
collect DBS at the diagnostic blood draw or another routine blood draw
from at least 90 percent of persons newly diagnosed with HIV at that
site/those sites annually?
Innovation: Does the project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support? Has the applicant demonstrated
collaborative planning by the State and local health department, the
State or local HIV diagnostic laboratory, and one or more HIV
diagnostic or clinical sites from which DBS can be obtained?
Protection of Human Subjects from Research Risks: Does the
application adequately address the requirements of 45 CFR part 46 for
the protection of human subjects? This will not be scored; however, an
application can be disapproved if the research risks are sufficiently
serious and protection against risks is so inadequate as to make the
entire application unacceptable.
Inclusion of Women and Minorities in Research: Does the application
adequately address the CDC Policy requirements regarding the inclusion
of women, ethnic, and racial groups in the proposed research? This
includes: (1) The proposed plan for the inclusion of both sexes and
racial and ethnic minority populations for appropriate representation;
(2) the proposed justification when representation is limited or
absent; (3) a statement as to whether the design of the study is
adequate to measure differences when warranted; and (4) a statement as
to whether the plans for recruitment and outreach for study
participants include the process of establishing partnerships with
community(ies) and recognition of mutual benefits.
Budget: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research.
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) and for responsiveness by NCHSTP. Incomplete
applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements.
Applications that are complete and responsive to the PA will be
evaluated for scientific and technical merit by an appropriate peer
review group or charter study section convened by NCHSTP in accordance
with the review criteria listed above. As part of the initial merit
review, all applications may:
Undergo a process in which only those
applications deemed to have the highest scientific merit, generally the
top half of the applications under review, will be discussed and
assigned a priority score.
Receive a written critique.
Receive a second level review by the CDC,
NCHSTP, Division of HIV/AIDS Prevention (DHAP) Senior Staff.
Award Criteria: Criteria that will be used to make award decisions
include:
Scientific merit (as determined by peer review).
Availability of funds.
[[Page 21121]]
Programmatic priorities.
V.3. Anticipated Announcement and Award Dates
September 17, 2004.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Grant Award (NGA)
from the CDC Procurement and Grants Office. The NGA shall be the only
binding, authorizing document between the recipient and CDC. The NGA
will be signed by an authorized Grants Management Officer, and mailed
to the recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
45 CFR part 74 and part 92. For more information on the Code of
Federal Regulations, see the National Archives and Records
Administration at the following Internet address: http://
www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-1 Human Subjects Requirements.
AR-2 Requirements for Inclusion of Women and
Racial and Ethnic Minorities in Research.
AR-4 HIV/AIDS Confidentiality Provisions.
AR-5 HIV Program Review Panel Requirements.
AR-7 Executive Order 12372.
AR-9 Paperwork Reduction Act Requirements.
AR-10 Smoke-Free Workplace Requirements.
AR-11 Healthy People 2010.
AR-12 Lobbying Restrictions.
AR-14 Accounting System Requirements.
AR-22 Research Integrity.
AR-24 Health Insurance Portability and
Accountability Act Requirements.
AR-25 Release and Sharing of Data.
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: http://www.cdc.gov/od/
pgo/funding/ARs.htm.
VI.3. Reporting
You must provide CDC with an original, plus two hard copies of the
following reports:
1. Interim progress report, (use form PHS 2590, OMB Number 0925-
0001, rev. 5/2001 as posted on the CDC Web site) no less than 90 days
before the end of the budget period. The progress report will serve as
your non-competing continuation application, and must contain the
following elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Budget.
e. Additional Requested Information.
f. Measures of Effectiveness.
2. Financial status report and annual progress report, no more than
90 days after the end of the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be mailed to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
VII. Agency Contacts
For general questions about this announcement, contact: Technical
Information Management Section, CDC Procurement and Grants Office, 2920
Brandywine Road, Atlanta, GA 30341; telephone: (770) 488-2700.
For scientific/research issues, contact: Diane Bennett, M.D.,
Extramural Project Officer, CDC, National Center for HIV, STD and TB
Prevention, Division of HIV/AIDS Prevention, 1600 Clifton Road, Mail-
Stop E-47, Atlanta, Georgia 30333; telephone: (404) 639-5349, e-mail:
[email protected].
For questions about peer review, contact: Andrew Vernon, Scientific
Review Administrator, CDC, National Center for HIV, STD and TB
Prevention, Office of the Director, Associate Director for Science,
1600 Clifton Road, Mail-S top E-07, Atlanta, Georgia 30333; telephone:
(404) 639-8000, e-mail: [email protected].
For financial, grants management, or budget assistance, contact:
Brenda Hayes, Grants Management Specialist, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, GA 30341; telephone: 770-488-
2741, e-mail: [email protected].
For financial, grants management, or budget assistance in the
territories, contact: Vincent Falzone, Contract Specialist, CDC
Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341;
telephone: 770-488-2763, e-mail: [email protected].
Dated: April 14, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 04-8875 Filed 4-19-04; 8:45 am]
BILLING CODE 4163-18-P